Advances in nonsurgical treatment of head and neck squamous cell carcinoma

doi:10.3760/cma.j.issn.1673-422X.2019.12.007

Abstract

Abstract: Locally advanced head and neck squamous cell carcinoma requires a multidisciplinary approach, including surgery followed by radiotherapy, with or without chemotherapy, or definitive concurrent chemoradiotherapy. The application of induction chemotherapy remains controversial. Cetuximab has achieved satisfactory results in the treatment of head and neck squamous cell carcinoma. Immunocheckpoint inhibitors against the receptor programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have demonstrated clinical efficacy in head and neck squamous carcinoma. However, only a small subset of patients can benefit from anti-PD-1 and anti-PD-L1 monotherapy. To improve the effectiveness of immunotherapy, combined of immunotherapy and other treatments has become an alternative strategy.

Key words: Head and neck neoplasms, Radiotherapy, Cetuximab, Immunotherapy, Chemotherapy

Zang Shoumei, Yan Danfang, Yan Senxiang. Advances in nonsurgical treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2019, 46(12): 741-744.

References ［28］

［1］	Mandal R, Şenbabaoğlu Y, Desrichard A, et al. The head and neck cancer immune landscape and itsimmunotherapeutic implications［J］. JCI Insight, 2016, 1 (17): e89829. DOI: 10.1172/jci.insight.89829.
［2］	Argiris A, Harrington KJ, Tahara M, et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck［J］. Front Oncol, 2017, 7: 72. DOI: 10.3389/fonc.2017.00072.
［3］	Lin W, Chen M, Hong L, et al. Crosstalk between PD-1/PD-L1 blockade and its combinatorial therapies in tumor immune microenvironment: a focus on HNSCC［J］. Front Oncol, 2018, 8: 532. DOI: 10.3389/fonc.2018.00532.
［4］	Semrau R. The role of radiotherapy in the definitive and postoperative treatment of advanced head and neck cancer［J］. Oncol Res Treat, 2017, 40(6): 347-352. DOI: 10.1159/000477128.
［5］	Leclerc M, Lartigau E, Lacornerie T, et al. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy［J］. Radiother Oncol, 2015, 116(1): 87-93. DOI: 10.1016/j.radonc.2015.06.007.
［6］	Margalit DN, Haddad RI, Tishler RB, et al. A phase 1 study of afatinib in combination with postoperative radiation therapy with and without weekly docetaxel in intermediate and high-risk patients with resected squamous cell carcinoma of the head and neck［J］. Int J Radiat Oncol Biol Phys, 2019, 105(1): 132-139. DOI: 10.1016/j.ijrobp.2019.04.034.
［7］	Jones TM, De M, Foran B, et al. Laryngeal cancer: United Kingdom National Multidisciplinary guidelines［J］. J Laryngol Otol, 2016, 130(S2): S75-S82. DOI: 10.1017/S0022215116000487.
［8］	Ghosh-Laskar S, Kalyani N, Gupta T, et al. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: results of a prospective randomized trial［J］. Head Neck, 2016, 38(2): 202-207. DOI: 10.1002/hed.23865.
［9］	Lee SY, Choi YS, Song IC, et al. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: a multicenter retrospective analysis［J］. Medicine (Baltimore), 2018, 97(21): e10778. DOI: 10.1097/MD.0000000000010778.
［10］	Szturz P, Wouters K, Kiyota N, et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data［J］. Oncologist, 2017, 22(9): 1056-1066. DOI: 10.1634/theoncologist.2017-0015.
［11］	Popovtzer A, Burnstein H, Stemmer S, et al. Phase Ⅱ organ-preservation trial: concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy［J］. Head Neck, 2017, 39(2): 227-233. DOI: 10.1002/hed.24571.
［12］	Busch CJ, Tribius S, Schafhausen P, et al. The current role of systemic chemotherapy in the primary treatment of head and neck cancer［J］. Cancer Treat Rev, 2015, 41(3): 217-221. DOI: 10.1016/j.ctrv.2015.02.002.
［13］	Hitt R, Grau JJ, López-Pousa A, et al. A randomized phase Ⅲ trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer［J］. Ann Oncol, 2014, 25(1): 216-225. DOI: 10.1093/annonc/mdt461.
［14］	Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. a phase Ⅱ-Ⅲ trial［J］. Ann Oncol, 2017, 28(9): 2206-2212. DOI: 10.1093/annonc/mdx299.
［15］	Kim R, Hahn S, Shin J, et al. The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis［J］. Cancer Res Treat, 2016, 48(3): 907-916. DOI: 10.4143/crt.2015.359.
［16］	Santuray RT, Johnson DE, Grandis JR. New therapies in head and neck cancer［J］. Trends Cancer, 2018, 4(5): 385-396. DOI: 10.1016/j.trecan.2018.03.006.
［17］	Granados-García M, Aguilar-Ponce JL, Maldonado-Magos F, et al. Advanced squamous cell carcinoma of the head and neck: the current role of cetuximab［J］. ORL J Otorhinolaryngol Relat Spec, 2016, 78(6): 320-333. DOI: 10.1159/000455891.
［18］	Colevas AD, Yom SS, Pfister DG, et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018［J］. J Natl Compr Canc Netw, 2018, 16(5): 479490. DOI: 10.6004/jnccn.2018.0026.
［19］	Mazorra Z, Lavastida A, Concha-Benavente F, et al. Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T Cells in head and neck cancer patients［J］. Front Pharmacol, 2017, 8: 382. DOI: 10.3389/fphar.2017.00382.
［20］	Chen Z, Xu XH. Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma［J］. Saudi Med J, 2015, 36(6): 659-664. DOI: 10.15537/smj.2015.6.11460.
［21］	Vassilakopoulou M, Psyrri A, Argiris A, et al. Targeting angiogenesis in head and neck cancer［J］. Oral Oncol, 2015, 51(5): 409-415. DOI: 10.1016/j.oraloncology.2015.01.006.
［22］	Ferris RL. Immunology and immunotherapy of head and neck cancer［J］. J Clin Oncol, 2015, 33(29): 3293-3304. DOI: 10.1200/JCO.2015.61.1509.
［23］	Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck［J］. N Engl J Med, 2016, 375(19): 1856-1867. DOI: 10.1056/NEJMoa-1602252.
［24］	Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study［J］. Lancet, 2019, 393(10167): 156-167. DOI: 10.1016/S0140-6736(18)31999-8.
［25］	Burtness B, Harrington KJ, Greil R, et al. LBA8_PRKEYNOTE-048: phase Ⅲ study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)［J］. Ann Oncol, Munich, 2018, 29(suppl_8). DOI: 10.1093/annonc/mdy424.045.
［26］	Wise-Draper TM, Old MO, Worden FP, et al. Phase Ⅱ multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma［J］. J Clin Oncol, 2018, 36(15_suppl): 6017. DOI: 10.1200/JCO.2018.36.15_suppl.6017.
［27］	Dong ZY, Zhang JT, Liu SY, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer［J］. Oncoimmunology, 2017, 6(11): e1356145. DOI: 10.1080/2162402X.2017.1356145.
［28］	Hata A, Katakami N, Nanjo S, et al. Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer［J］. Oncotarget, 2017, 8(69): 113807-113816. DOI: 10.18632/oncotarget.22837.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[7]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[8]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[11]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.
[14]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[15]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.